MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects

Original Paper

Abstract

Purpose

Published data on the association between manganese superoxide dismutase (MnSOD) Val16Ala polymorphism and prostate cancer (PCA) risk are inconclusive. To derive a more precise estimate of the association between them, a meta-analysis was performed.

Methods

PubMed and Embase were searched. All eligible studies were retrieved. The pooled odds ratio (OR) with 95% confidence interval (CI) for PCA risk associated with Val/Ala versus Val/Val, Ala/Ala versus Val/Val, dominant model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val) were estimated, respectively.

Results

A total of 12 studies including 8,962 subjects were involved in this meta-analysis. Overall, the meta-analysis indicated that significantly elevated cancer risk was associated with Ala variant genotype when all the eligible studies were pooled into the meta-analysis (for Val/Ala vs. Val/Val: OR = 1.11, 95% CI = 1.00–1.24; for Ala/Ala vs. Val/Val: OR = 1.22, 95% CI = 1.00–1.49; for dominant model: OR = 1.14, 95% CI = 1.03–1.26). In the subgroup analysis by ethnicity, statistically significant increased risks were found among Caucasians with Ala allele (for Val/Ala vs. Val/Val: OR = 1.12, 95% CI = 1.00–1.25; for dominant model: OR = 1.14, 95% CI = 1.02–1.26). However, no significant associations were found in Africans.

Conclusions

This meta-analysis suggests that the Ala allele of the MnSOD gene was a low-penetrance susceptible gene in PCA development, especially in Caucasians.

Keywords

MnSOD Polymorphism Prostate cancer Susceptibility Meta-analysis 

References

  1. Arsova-Sarafinovska Z, Matevska N, Petrovski D et al (2008) Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer. Cell Biochem Funct 26:771–777CrossRefPubMedGoogle Scholar
  2. Arundhati B, Niladri B (2008) Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review. Cancer Epidemiol Biomarkers Prev 17:3298–3305CrossRefGoogle Scholar
  3. Baker AM (1997) Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 32:229–233CrossRefPubMedGoogle Scholar
  4. Bica CG, da Silva LL, Toscani NV et al (2009) MnSOD gene polymorphism association with steroid-dependent cancer. Pathol Oncol Res 15:19–24CrossRefPubMedGoogle Scholar
  5. Choi JY, Neuhouser ML, Barnett M et al (2007) Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol Biomarkers Prev 16:1115–1120CrossRefPubMedGoogle Scholar
  6. Choi JY, Neuhouser ML, Barnett MJ et al (2008) Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis 29:964–970CrossRefPubMedGoogle Scholar
  7. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRefGoogle Scholar
  8. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  9. Duan H, Zhang HJ, Yang JQ, Oberley LW, Futscher BW, Domann FE (2003) MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxid Redox Signal 5:677–688CrossRefPubMedGoogle Scholar
  10. Egger M, Smith DG, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  11. Ergen HA, Narter F, Timirci O, Isbir T (2007) Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case–control study. Anticancer Res 27:1227–1230PubMedGoogle Scholar
  12. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–51CrossRefPubMedGoogle Scholar
  13. Iguchi T, Wang CY, Delongchamps NB et al (2008) Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology 72:238–241. Discussion 241–242CrossRefPubMedGoogle Scholar
  14. Iguchi T, Sugita S, Wang CY, Newman NB, Nakatani T, Haas GP (2009) MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo 23:7–12PubMedGoogle Scholar
  15. Kang D, Lee KM, Park SK et al (2007) Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 16:1581–1586CrossRefPubMedGoogle Scholar
  16. Li N (1998) Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate 35:221–233CrossRefPubMedGoogle Scholar
  17. Li H, Kantoff PW, Giovannucci E et al (2005) Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65:2498–2504CrossRefPubMedGoogle Scholar
  18. Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMedGoogle Scholar
  19. Liwei L, Chunyu L, Ruifa H (2009) Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis. Urology. 30 July 2009 [Epub ahead of print]Google Scholar
  20. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  21. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW (2008) Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 29:2335–2340CrossRefPubMedGoogle Scholar
  22. Millikan RC, Player J, de Cotret AR (2004) Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case–control study of African Americans and whites. Breast Cancer Res 6:R264–R274CrossRefPubMedGoogle Scholar
  23. Rosenblum JS (1996) On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci USA 93:4471–4473CrossRefPubMedGoogle Scholar
  24. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F (2003) The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13:145–157CrossRefPubMedGoogle Scholar
  25. Taylor SJ, Tweedie RI (1998) Practical estimates of the effect of publication bias in meta- analysis. Australas Epidemiol 5:14–17Google Scholar
  26. Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar
  27. Venkataraman S, Jiang X, Weydert C (2005) Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene 24:77–89CrossRefPubMedGoogle Scholar
  28. Wacholder S, Chanock S, Garcia-Closas M (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–440PubMedCrossRefGoogle Scholar
  29. Wang LI, Neuberg D, Christiani DC (2004) Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. J Occup Environ Med 46:556–564CrossRefPubMedGoogle Scholar
  30. Woodson K, Tangrea JA, Lehman TA et al (2003) Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14:513–518CrossRefPubMedGoogle Scholar
  31. Zhong WX (1997) Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 14:481–490CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of Epidemiology, School of Public Health and Tropical MedicineSouthern Medical UniversityGuangzhouChina
  2. 2.Department of Medical Oncology, Cancer HospitalFudan UniversityShanghaiPeople’s Republic of China
  3. 3.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  4. 4.Department of Respiratory MedicineNanjing Chest HospitalNanjingChina
  5. 5.Longgang Center for Disease Control and Prevention of ShenzhenShenzhenChina
  6. 6.Department of Respiratory MedicineHefei Second People’s HospitalHefeiChina

Personalised recommendations